Overview
| Name | AIntibody · aliases: AIntibody, AIntibody challenge |
|---|---|
| Full name | The organizers use only the name AIntibody; no expanded form exists. |
| Ambiguous names (not auto-linked) | None |
| Family | Not a family entry. Only one completed round exists, so there are no family members. |
| Domain | Antibodies (also: Proteins) |
| Inclusion | Supplementary entry |
| Type | A · Prospective blind challenge scored per task. |
| Evidence level | L5 · Blind test with prospective wet-lab work under uniform protocols; no independent replication. |
| Publisher | Specifica (IQVIA) (Platform company) |
| First release | Basis: Challenge design paper online (Nature Biotechnology, 10.1038/s41587-024-02469-9) source |
| Other milestones | |
| Latest update | · data Basis: Results paper online (Nature Biotechnology) Round-1 results paper online: 29 organizations submitted 511 sequences, measured for affinity and developability; vendor releases followed on 2026-08-27. source The most recent sourced event, not a claim that nothing changed since. |
| Next expected | Secondary reports say a society will run the next round, but the organizers have announced no date or target. |
| Status | ◐ Low-frequency · First round finished; the next round's host appears only in secondary reports, with no date or target. |
| Scale | 29 organizations submitted 511 sequences across 3 tasks; fewer than 511 unique sequences were actually tested.
|
| Wet-lab refresh | Fresh experiments each round · New measurements each round: affinity by both HT-SPR and KinExA, and a five-assay developability panel run by independent laboratories under uniform protocols. |
| Own wet lab needed to evaluate a new model | No, run it as a download |
| Models reported | 1 counted (board 1, unconfirmed 1) |
| Unverified fields | † ranking.entries[1], ranking.caveat, next_expected, models_reported[0] |
| As of | 2026-11-16 |
What it measures
- Task: Three tasks: computational affinity maturation from sequencing output, ranking affinity within HCDR3 clusters, and de novo CDR design against a protein absent from the selection output.
- Truth: Newly measured experimental results under uniform protocols: affinity plus five developability assays, against SARS-CoV-2 spike RBD.
- Primary metric: Measured equilibrium dissociation constant KD.
- Secondary metrics: Whether the five developability thresholds are passed.
- Version traps: Placements cannot be pooled across the three tasks; headline numbers need the task and assay method, and participation counts differ between vendor releases and the paper.
Current ranking
Board
| Metric | Measured KD (HT-SPR and KinExA) plus five developability screens; placement per task |
|---|---|
| Eval set | AIntibody round 1, 3 challenges, 511 submitted sequences from 29 organizations, SARS-CoV-2 spike RBD |
| Snapshot | |
| Board | https://doi.org/10.1038/s41587-026-03238-6 |
| Retrieved | 2026-11-16 |
Caveat. The results paper is paywalled, so figures come from vendor releases and the site's earlier note; placements sit with organizations or internal models, vendor claims conflict, and task 3 values must not be mixed with task 1.
Shown in the overview table: Board
| Rank | Model | Score (verbatim) | Metric · eval set / protocol | Source type · date | Source and note |
|---|---|---|---|---|---|
| 1 | AuraIDE / AuraBind (Aureka Biotechnologies, internal model) | KD 94.7 pM (KinExA); best experimental antibody 113 pM | Measured KD (HT-SPR and KinExA) plus five developability screens; placement per task AIntibody round 1, 3 challenges, 511 designs from 29 organizations, SARS-CoV-2 spike RBD; all designs made and measured in one lab | Board | source Not a site model; first in task 1, with second and fifth also reported by the same organization; any link to open weights is a company statement only. |
| 3 | IgGM (Tencent AI4S) | No score | Measured KD (HT-SPR and KinExA) plus five developability screens; placement per task AIntibody round 1, 3 challenges, 511 designs from 29 organizations, SARS-CoV-2 spike RBD; all designs made and measured in one lab | Self-reported † | source Developer claims a top-three placement in a 2025-08 repository entry; no value, no task named, not confirmed in official materials. |
Models reported
Grouped by relation type; each line shows its source type. Counted relations add up to 1. A pairing whose evidence rests only on this survey's own page is shown as unverified.
Official leaderboard or results (1)
- IgGM / IgGM-FM Board · The team claims a top-three placement in the affinity-optimization task; no per-team standing is cited and official materials do not confirm it. low confidence †unverified · evidence: link
Unconfirmed (1, not counted)
- OpenDDE Unconfirmed source Challenge 1 (computational affinity maturation) · The placement belongs to that company's internal model and cannot be credited to the open weights; the site matrix and model page disagree. Resolution: Ruled unconfirmed: the public weights cannot be matched to the competition entry. †disputed · evidence: link
Caveats
- The paper's conclusion is conservative: results do not transfer across tasks and most designs did not beat conventional screening.
- Except for one model, predicting high-affinity clones within HCDR3 clusters did worse than picking at random.
- Participation and submission counts differ between sources, and much of the coverage is vendor press releases.
- A single 2.9 pM winning claim appears only on social media, with no public confirmation that it passed developability screening.
- Placements sit with organizations or internal models, open weights have no attributable placement, and there is no independent replication.
How to use it
There is no open submission: either wait for the next round or reproduce the same pipeline. Screen internally on the AbBiBench and FLAb retrospective sets first, then keep a prospective arm. Report the three tasks separately without pooling placements, and give the assay method, KD and all five developability results with the number of sequences tested.
Pairs well with: Ginkgo GDPa1 · AbBiBench · FLAb / FLAb2 · FoldBench · Adaptyv competitions / BenchBB
Sources
- AIntibody results paper (Nature Biotechnology 2026) (journal) ·
- AIntibody challenge design paper (Nature Biotechnology 2024) (journal) ·
- Press coverage: results and next-round arrangements (press)
- Press coverage: vendor placement claims and the next round's host (press)
- Company press release (syndicated) (press)
Corrections
4 corrections
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| scale | 511 designs from 29 organizations; same-lab KinExA plus five developability assays; 14 days / max 10 sequences per task | 511 submitted sequences from 29 organizations; affinity by HT-SPR and KinExA; five-assay developability panel run by independent laboratories under uniform protocols; fewer than 511 unique sequences were actually tested | source | 2026-11-16 |
| scale | 14 days and at most 10 sequences per team per task | removed | source | 2026-11-16 |
| wetlab_note | fresh KinExA affinity and five developability assays in one lab | HT-SPR and KinExA affinity, five-assay developability panel run by independent laboratories under uniform protocols | source | 2026-11-16 |
| models_reported | leaderboard entry recorded for the open-weight model | disputed-or-unconfirmed; the placement belongs to a company-internal model | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 44 benchmarks · open in the explorer. Record as of 2026-11-16.